18F-FDG-PET/CT predicts early tumor recurrence in living donor liver transplantation for hepatocellular carcinoma

Transplant International

Volumn 26, Issue 1, 2013, Pages 50-60

  Lee, Seung Duk ^a   Kim, Seong Hoon ^a   Kim, Young Kyu ^a   Kim, Chulhan ^a   Kim, Seok Ki ^a   Han, Sung Sik ^a   Park, Sang Jae ^a  

^a National Cancer Center   (South Korea)

Author keywords

18F fluorodeoxyglucose; liver transplantation; positron emission tomography; prognosis; recurrence

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; ARTICLE; CANCER GRADING; CANCER INVASION; CANCER PROGNOSIS; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DISEASE FREE SURVIVAL; EARLY DIAGNOSIS; FEMALE; HEPATITIS B; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER METASTASIS; LIVER NODULE; LIVER TRANSPLANTATION; LIVING DONOR; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREDICTIVE VALUE; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; TUMOR DIFFERENTIATION; TUMOR RECURRENCE; TUMOR VOLUME;

ADULT; AGED; CARCINOMA, HEPATOCELLULAR; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; LIVING DONORS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PROGNOSIS; RADIOPHARMACEUTICALS;

EID: 84871259993     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2012.01572.x     Document Type: Article

References (31)

1. Ishizaki Y, Kawasaki S,. The evolution of liver transplantation for hepatocellular carcinoma (past, present, and future). J Gastroenterol 2008; 43: 18.
2. Mazzaferro V, Regalia E, Doci R, etal. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Eng J Med 1996; 334: 693.
3. Roayaie S, Schwartz JD, Sung MW, etal. Recurrence of hepatocellular carcinoma after liver transplant: patterns and prognosis. Liver Transplant 2004; 10: 534.
4. Yao FY, Ferrell L, Bass NM, etal. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 2001; 33: 1394.
5. Chen CL, Fan ST, Lee SG, Makuuchi M, Tanaka K,. Living-donor liver transplantation: 12 years of experience in Asia. Transplantation 2003; 75: S6.
6. Lo CM, Fan ST, Liu CL, Chan SC, Wong J,. The role and limitation of living donor liver transplantation for hepatocellular carcinoma. Liver Transplant 2004; 10: 440.
7. Soejima Y, Taketomi A, Yoshizumi T, etal. Extended indication for living donor liver transplantation in patients with hepatocellular carcinoma. Transplantation 2007; 83: 893.
8. Toso C, Asthana S, Bigam DL, Shapiro AM, Kneteman NM,. Reassessing selection criteria prior to liver transplantation for hepatocellular carcinoma utilizing the Scientific Registry of Transplant Recipients database. Hepatology 2009; 49: 832.
9. Schwartz M, Roayaie S, Uva P,. Treatment of HCC in patients awaiting liver transplantation. Am J Transplant 2007; 7: 1875.
10. Lee JW, Paeng JC, Kang KW, etal. Prediction of tumor recurrence by 18F-FDG PET in liver transplantation for hepatocellular carcinoma. J Nucl Med 2009; 50: 682.
11. Kornberg A, Freesmeyer M, Barthel E, etal. 18F-FDG-uptake of hepatocellular carcinoma on PET predicts microvascular tumor invasion in liver transplant patients. Am J Transplant 2009; 9: 592.
12. Jerusalem G, Hustinx R, Beguin Y, Fillet G,. The value of positron emission tomography (PET) imaging in disease staging and therapy assessment. Ann Oncol 2002; 13 (Suppl. 4): 227.
13. Edmondson HA, Steiner PE,. Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer 1954; 7: 462.
14. Kim SH, Cho SY, Park SJ, etal. Learning curve for living-donor liver transplantation in a fledgling cancer center. Transpl Int 2009; 22: 1164.
15. Cheng SJ, Pratt DS, Freeman Jr RB, Kaplan MM, Wong JB,. Living-donor versus cadaveric liver transplantation for non-resectable small hepatocellular carcinoma and compensated cirrhosis: a decision analysis. Transplantation 2001; 72: 861.
16. Sarasin FP, Majno PE, Llovet JM, Bruix J, Mentha G, Hadengue A,. Living donor liver transplantation for early hepatocellular carcinoma: A life-expectancy and cost-effectiveness perspective. Hepatology 2001; 33: 1073.
17. Mazzaferro V, Chun YS, Poon RT, etal. Liver transplantation for hepatocellular carcinoma. Ann Surg Oncol 2008; 15: 1001.
18. Zavaglia C, De Carlis L, Alberti AB, etal. Predictors of long-term survival after liver transplantation for hepatocellular carcinoma. Am J Gastroenterol 2005; 100: 2708.
19. Del Gaudio M, Grazi GL, Principe A, etal. Influence of prognostic factors on the outcome of liver transplantation for hepatocellular carcinoma on cirrhosis: a univariate and multivariate analysis. Hepatogastroenterology 2004; 51: 510.
20. Taouli B, Krinsky GA,. Diagnostic imaging of hepatocellular carcinoma in patients with cirrhosis before liver transplantation. Liver Transplant 2006; 12: S1.
21. Sotiropoulos GC, Malago M, Molmenti E, etal. Liver transplantation for hepatocellular carcinoma in cirrhosis: is clinical tumor classification before transplantation realistic? Transplantation 2005; 79: 483.
22. Takada Y, Ito T, Ueda M, etal. Living donor liver transplantation for patients with HCC exceeding the Milan criteria: a proposal of expanded criteria. Digest Dis 2007; 25: 299.
23. Yang SH, Suh KS, Lee HW, etal. The role of (18)F-FDG-PET imaging for the selection of liver transplantation candidates among hepatocellular carcinoma patients. Liver Transplant 2006; 12: 1655.
24. Mocherla B, Kim J, Roayaie S, Kim S, Machac J, Kostakoglu L,. FDG PET/CT imaging to rule out extrahepatic metastases before liver transplantation. Clin Nucl Med 2007; 32: 947.
25. Sugiyama M, Sakahara H, Torizuka T, etal. 18F-FDG PET in the detection of extrahepatic metastases from hepatocellular carcinoma. J Gastroenterol 2004; 39: 961.
26. Ho CL, Yu SC, Yeung DW,. 11C-acetate PET imaging in hepatocellular carcinoma and other liver masses. J Nucl Med 2003; 44: 213.
27. Shiomi S, Nishiguchi S, Ishizu H, etal. Usefulness of positron emission tomography with fluorine-18-fluorodeoxyglucose for predicting outcome in patients with hepatocellular carcinoma. Am J Gastroenterol 2001; 96: 1877.
28. Seo S, Hatano E, Higashi T, etal. Fluorine-18 fluorodeoxyglucose positron emission tomography predicts tumor differentiation, P-glycoprotein expression, and outcome after resection in hepatocellular carcinoma. Clin Cancer Res 2007; 13: 427.
29. Jonas S, Bechstein WO, Steinmuller T, etal. Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis. Hepatology 2001; 33: 1080.
30. Sumie S, Kuromatsu R, Okuda K, etal. Microvascular invasion in patients with hepatocellular carcinoma and its predictable clinicopathological factors. Ann Surg Oncol 2008; 15: 1375.
31. Lai Q, Melandro F, Pinheiro RS, etal. Alpha-fetoprotein and novel tumor biomarkers as predictors of hepatocellular carcinoma recurrence after surgery: a brilliant star raises again. Int J Hepatol 2012; 2012: 893103.